Dr. Edward Kim on Indicating Patient Populations With Biomarkers in NSCLC

Video

Edward Kim, MD, chair of the department of Solid Tumor Oncology, Levine Cancer Institute, discusses the further work that needs to be done when indicating patient populations with certain biomarkers in non-small cell lung cancer (NSCLC).

Edward Kim, MD, chair of the department of Solid Tumor Oncology, Levine Cancer Institute, discusses the further work that needs to be done when indicating patient populations with certain biomarkers in non-small cell lung cancer (NSCLC). Kim says while biomarkers can be useful, there is a hypothetical gradient that exists with patients and their biomarkers, and defining who that patient population is must show a distinct difference between the existing populations.

Related Videos
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Related Content
FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

November 29th 2023
Article

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Read More

Strategies for Neoadjuvant NSCLC Treatment

Strategies for Neoadjuvant NSCLC Treatment

September 1st 2023
Podcast

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Listen

KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC

KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC

November 27th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.

Read More

Therapies on the Horizon in EGFR Exon 20–Positive Lung Cancer

Therapies on the Horizon in EGFR Exon 20–Positive Lung Cancer

January 15th 2021
Podcast

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

Listen

Behind the FDA Approval of Enzalutamide for Prostate Cancer

Behind the FDA Approval of Enzalutamide for Prostate Cancer

November 22nd 2023
Article

Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.

Read More

BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL

BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL

November 20th 2023
Article

In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.

Read More